ArticleLung cancer (Amsterdam, Netherlands)2018
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
Article in Lung cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Therapy with Immune Checkpoint Inhibitors for Solid Tumors in Patients with Preexisting Systemic Autoimmune Diseases.Journal of clinical medicine · 2025Review
- Article
- Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.Blood advances · 2023Article
- Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases.RMD open · 2023Article
- Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease.JTO clinical and research reports · 2022Article
- Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease.Translational lung cancer research · 2021Review
- Lung Cancer Survival in Patients With Autoimmune Disease.JAMA network open · 2020Article
- Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study.Annals of translational medicine · 2020Article
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.Seminars in cancer biology · 2020Review
- The utility of histological subtype for predicting survival of lung cancer patients with rheumatoid arthritis.Translational cancer research · 2020Article
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.Nature reviews. Clinical oncology · 2019Review
- Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer.Medical sciences (Basel, Switzerland) · 2019Review
- Immune dysregulation in cancer patients developing immune-related adverse events.British journal of cancer · 2019Article
- An ontology-guided semantic data integration framework to support integrative data analysis of cancer survival.BMC medical informatics and decision making · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe advent of cancer immunotherapy has made autoimmune disease in oncology populations clinically important. We analyzed the association of autoimmune disease with treatment and outcomes among lung cancer patients.
methodsUsing linked Surveillance Epidemiology and End Results (SEER)-Medicare data, we identified lung cancer patients diagnosed between 1992 and 2009 with autoimmune diseases. We recorded number and timing of autoimmune disease diagnoses, lung cancer treatment, and markers of healthcare utilization including emergency department visits, hospitalizations, and outpatient visits. To account for potential lead-time bias, we used a matched case-control analysis wherein living and deceased patients were matched on survival time. We performed unadjusted and multivariable adjusted logistic regressions separately by cancer stage for all-cause and lung cancer-specific mortality.
resultsAmong 172,285 lung cancer patients, 23,084 (13.4%) had ≥1 autoimmune disease at any time. Overall, 10,927 patients (6.3%) had one autoimmune disease before cancer diagnosis; 9338 (5.4%) had two or more before cancer diagnosis; and 2819 (1.6%) had one or more after cancer diagnosis. Healthcare utilization was higher in the autoimmune disease population. Lung cancer treatment patterns were similar among patients with and without autoimmune disease and there was no significant association with mortality.
conclusionsAmong patients with lung cancer, autoimmune disease does not influence treatment patterns and is not associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.